Key result
BioLAB Mono stentless aortic valve replacement is linked to ~4% early mortality and low pressure gradients.
Why the study?
Does aortic valve replacement with the 'BioLAB Mono' stentless bioprosthesis provide adequate hemodynamic performance in patients with severe aortic stenosis?
Observational (n=27)
Does aortic valve replacement with the 'BioLAB Mono' stentless bioprosthesis provide adequate hemodynamic performance in patients with severe aortic stenosis?
The 'BioLAB Mono' stentless bioprosthesis demonstrates excellent early hemodynamic performance and is safe for aortic valve replacement in severe aortic stenosis.
Supports acceptable early BioLAB Mono performance in aortic stenosis; leaves open randomized comparisons to established prostheses.
AIM: To evaluate prospectively the hemodynamic performance of «BioLAB Mono» stentless bioprosthesis implanted into aortic position. MATERIAL AND METHODS: Twenty seven patients (mean age 71 (67; 73); 17 women) with severe aortic stenosis underwent aortic valve replacement with «BioLAB Mono» stentless bioprosthesis from 2012 to 2014. The valves were implanted into supra-annular position using continuous polypropylene suture. RESULTS: In the early postoperative period 1 patient (3.7%) died for acute heart failure. The mean aortic cross-clamping time was 81 (75; 90) min. Echocardiographic peak pressure gradient were 18 (16; 23) mmHg (postoperative). There were no cases of valve dysfunction in early postoperative period. Level of thrombocytes recovered after 10 days postoperatively. CONCLUSION: «BioLAB Mono» aortic bioprosthesis implantation is easy and reproducible. The valve has excellent hemodynamic performance in early postoperative period.
No takes yet. Share an insight, caveat, or question.
Астапов et al. (2016) conducted an observational in severe aortic stenosis (n=27). «BioLAB Mono» stentless bioprosthesis was evaluated on hemodynamic performance and early mortality. Aortic valve replacement with the BioLAB Mono stentless bioprosthesis resulted in a postoperative peak pressure gradient of 18 mmHg and an early mortality rate of 3.7%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: